Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Выпуски:
Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2016016222
pages 479-503

Regulatory T-Cell Therapy in Transplantation and Severe Autoimmunity

Maura Rossetti
Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
Roberto Spreafico
Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, CA

Краткое описание

Current approaches to prevent or treat transplant rejection, graft-versus-host disease and severe autoimmunity rely on non-specific immunosuppressive drugs. Ongoing efforts aimed at harnessing regulatory T (Treg) cells hold promise for revolutionizing the current therapeutic options, reducing if not abandoning immune suppression in favor of immune tolerance. This paradigm shift carries the potential of dramatically enhancing efficacy, persistency, and specificity while reducing side effects. Here, we review the various strategies devised to manipulate Treg cells in vitro and in vivo, the clinical progress achieved to date, and critical issues that still need to be addressed.

Ключевые слова: Treg cells, FOXP3, immune tolerance, low-dose IL-2, GvHD

Articles with similar content:

Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Crystal L. Mackall, Rimas J. Orentas
Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma
Critical Reviews™ in Immunology, Vol.38, 2018, issue 3
Amanda Teets, Linda Pham, Rahul Deshmukh, Lana Hochmuth, Emma Lan Tran
Tolerance and Cancer: A Critical Issue in Tumor Immunology
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 5-6
Hyam I. Levitsky, Eduardo M. Sotomayor, Ivan Borrello
A Chimerism-Based Approach to Induce Tolerance in IgE-Mediated Allergy
Critical Reviews™ in Immunology, Vol.29, 2009, issue 5
Ulrike Baranyi, Martina Gattringer, Thomas Wekerle, Nina Pilat
Engineered Nanocarriers of Doxorubicin: A Current Update
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 1
Swati A. Guhagarkar, Rajesh R. Patil, Padma V. Devarajan